Principles of therapy of vascular occlusion in facial area provoked by introduction of calcium hydroxyapatite
https://doi.org/10.33667/2078-5631-2022-8-100-103
Abstract
The use of dermal fllers based on calcium hydroxyapatite has become widespread among cosmetologists. These fllers are considered highly effective in the fght against age-related skin changes, have a high safety profle and are not prone to cause an autoimmune response of the body. Due to specifcs of the fller, calcium hydroxyapatite provides both restoration of soft tissue volume loss and stimulation of neocollagenesis. Having a long experience of use, the fller has frmly taken its place in aesthetic medicine and is successfully used by many doctors around the world. However, with the increase in the use of fllers, the number of side effects also increases. Currently, there are no clear guidelines for the treatment of complications of injection by calcium hydroxyapatite, unlike fllers based on hyaluronic acid. Despite the low risk of developing serious complications as a result of unintentional vascular occlusion, a number of doctors are afraid to use calcium hydroxyapatite preparations due to lack of knowledge on its elimination. This article describes the basic principles of therapy for occlusive syndrome and can help doctors to take effective and timely therapeutic measures to correct it.
About the Authors
E. V. Ikonnikova
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Russian Federation
Ikonnikova Evgenia V., associate professor at Dept of Dermatology and Cosmetology
N. E. Manturova
Russian National Research Medical University n.a. N.I. Pirogov
Russian Federation
Russian Federation
Manturova Natalya E., DM Sci (habil.), professor, head of Dept of Plastic and Reconstructive Surgery, Cosmetology and Cellular Technologies
O. A. Golanova
Lancet – Centre’ Clinic
Russian Federation
Russian Federation
Golanova Olga A., cosmetologist
References
1. Loghem J.V., Yutskovskaya Y.A., Werschler P.W. Calcium hydroxyapatite: over a decade of clinical experience. The Journal of clinical and aesthetic dermatology. 2015; 8 (1): 38–49.
2. Cho K.H., Uthaman S., Park I.K., Cho C.S. Injectable Biomaterials in Plastic and Reconstructive Surgery: A Review of the Current Status. Tissue engineering and regenerative medicine. 2018; 15 (5), 559–574. https://doi.org/10.1007/s13770–018–0158–2
3. Szczerkowska-Dobosz A., Olszewska B., Lemańska M., Purzycka-Bohdan D., Nowicki R. Acquired facial lipoatrophy: pathogenesis and therapeutic options. Postepy dermatologii i alergologii. 2015; 32 (2), 127–133. https://doi.org/10.5114/pdia.2014.40971
4. Zerbinati N., D’Este E., Parodi P.C., Calligaro A. Microscopic and ultrastructural evidences in human skin following calcium hydroxylapatite fller treatment. Archives of dermatological research. 2017; 309 (5): 389–396. https://doi:10.1007/s00403–017–1734–3
5. Bentkover S. H. The Biology of Facial Fillers. Facial Plastic Surgery. 2009; 25: 73–85. Doi: 10.1055/s-0029–1220646.
6. Pavicic T. Complete biodegradable nature of calcium hydroxylapatite after injection for malar enhancement: an MRI study. Clinical, cosmetic and investigational dermatology. 2015; 8: 19–25. DOI: 10.2147/CCID.S72878.
7. Yutskovskaya Y., Kogan E., Leshunov E. A randomized, split-face, histomorphologic study comparing a volumetric calcium hydroxylapatite and a hyaluronic acid-based dermal fller. Journal of drugs in dermatology. 2014; 13 (9): 1047–52.
8. Marmur E..S, Phelps R., Goldberg D.J. Clinical, histologic and electron microscopic fndind after injection of a calcium hydroxylapatite fller. Journal of cosmetic and laser therapy: offcial publication of the European Society for Laser Dermatology. 2004; 6 (4): 223–6. DOI: 10.1080/147641704100003048.
9. van Loghem J., Funt D., Pavicic T., Goldie K., Yutskovskaya Y., Fabi S., Siebenga P., Thuis J., Hkeik J., Kadouch J., Prager W., Azib N., Casabona G., Dayan S., Bay Aguilera S, Snozzi P., Saeed P. Managing intravascular complications following treatment with calcium hydroxylapatite: An expert consensus. Journal of cosmetic dermatology. 2020; 19 (11), 2845–2858. https://doi.org/10.1111/jocd.13353
10. King M., Walker L., Convery C., Davies E. Management of a Vascular Occlusion Associated with Cosmetic Injections. The Journal of clinical and aesthetic dermatology. 2020; 13 (1): E53–E58.
11. Ikonnikova E. V., Stenko A. G., Chaikovskaya E. A., Zmazova V. G. Complication of injection rhinoplasty. Plastic surgery and aesthetic medicine. 2019; 4: 76–81. https://doi.org/10.17116/plast.hirurgia201904176
12. Hong J.Y., Seok J., Ahn G.R., Jang Y.J., Li K., Kim B.J. Impending skin necrosis after dermal fller injection: A ‘golden time’ for frst-aid intervention. Dermatologic Therapy. 2016; 30 (2), e12440. DOI: 10.1111/dth.12440.
13. Beer K., Downie J., Beer J.. A treatment protocol for vascular occlusion from particulate soft tissue augmentation. The Journal of clinical and aesthetic dermatology. 2012; 5 (5): 44–47.
14. Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clinical Nephrology. 1985; 23: 63–7.
15. Robinson D.M. In Vitro Analysis of the Degradation of Calcium Hydroxylapatite Dermal Filler: A Proof – of – Concept Study. Dermatologic Surgery offcial publication for American Society for Dermatologic Surgery. 2018; 44, S5–S9. DOI: 10.1097/DSS.0000000000001683.
16. Pasch A., Schaffner T., Huynh-Do U., Frey B.M. Sodium thiosulfate prevents vascular calcifcations in uremic rats. Kidney Internation. 2008; 74: 1444–53. DOI: 10.1038/ki.2008.455.
17. Danysz W., Nowag B., Hengl T., Kreymerman P., Furne C., Madeuf E., Höennscheidt C., Mraz Robinson D. Can Sodium Thiosulfate Act as a Reversal Agent for Calcium Hydroxylapatite Filler? Results of a Preclinical Study. Clinical, cosmetic and investigational dermatology. 2020; 13, 1059–1073. https://doi.org/10.2147/CCID.S271760
18. Henderson R., Reilly D.A.., Cooper JS. Hyperbaric Oxygen for Ischemia due to Injection of Cosmetic Fillers: Case Report and Issues. Plastic and reconstructive surgery. 2018; 11; 6 (1). DOI: 10.1097/GOX.0000000000001618.
19. Thom S.R. Hyperbaric oxygen: its mechanisms and effcacy. Plastic and reconstructive surgery. 2011; 127 Suppl 1 (Suppl 1): 131S-141S. DOI: 10.1097/PRS.0b013e3181fbe2bf.
20. Menchisheva Y., Mirzakulova U., Rudolf Y. Use of platelet-rich plasma to facilitate wound healing. Internation Wourd Journal. 2019; 16 (2): 343–353. DOI: 10.1111/iwj.13034.
21. Kang B.K., Kang I.J., Jeong K.H., Shin M.K. Treatment of glabella skin necrosis following injection of hyaluronic acid fller using platelet-rich plasma. Journal Cosmetic and Laser therapy: offcial publication of the European Society for Laser Dermatology. 2016; 18 (2): 111–112. DOI: 10.3109/14764172.2015.1052512.
22. Aksenenko I.P. Combined use of enzyme and carboxytherapy for complications of contouring of the hand area in cosmetology. Physiotherapy, balneology and rehabilitation, 19, No. 2, Pp.: 83–89, 2020. DOI: 10.17816/1681–3456–2020–19–2–3.
23. Casabona G. Blood aspiration test for cosmetic fllers to prevent accidental intravascular injection in the face. Dermatologic Surgery: for American Society for Dermatologic Surgery. 2015; 41 (7): 841–847. Doi: 10.1097/Dss.0000000000000395.
24. Robati R.M., Moeineddin F., Almasi-Nasrabadi M. The Risk of Skin Necrosis Following Hyaluronic Acid Filler Injection in Patients with a History of Cosmetic Rhinoplasty. Aesthetic surgery journal. 2018; 38 (8), 883–888. https://doi.org/10.1093/asj/sjy005
Review
For citations:
Ikonnikova E.V., Manturova N.E., Golanova O.A. Principles of therapy of vascular occlusion in facial area provoked by introduction of calcium hydroxyapatite. Medical alphabet. 2022;(8):100-103. (In Russ.) https://doi.org/10.33667/2078-5631-2022-8-100-103
Views:
486
Email this article 